

CIN No.: U74900MH2013PLC244717

Date: June 12, 2025

To:

Indorient Financial Services Limited B/805, Rustomjee Central Park, Andheri Kurla Road, Chakala, Mumbai – 400093, Maharashtra, India

Dear Sir,

Re: Proposed Initial Public Offering of equity shares of Rs. 10 [Rupees Ten Only] each ("Equity Shares") by Aakaar Medical Technologies Limited ("Company") (the "Issue" or "IPO")

Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA

Mob: +91 920317468

www.aakaarmedical.in GST No: 27AALCA7587Q1ZK

E-mail: info@aakaarmedical.in

Sub: Capital Structure and Notes to Capital Structure

This is to certify that the disclosures and undertakings pertaining to the capital structure and the notes to capital structure in relation to the IPO, as contained in 'Annexure A' hereto are true, fair and correct, not misleading and without omission of any matter that is likely to mislead, and adequate to enable investors to make a well informed decision and, accordingly may be incorporated in the Red Herring Prospectus intended to be filed by the Company with the NSE Emerge, and the Red Herring Prospectus and the Prospectus intended to be filed by the Company with NSE Emerge and the Registrar of Companies, Mumbai ("RoC"), with respect to the said IPO.

We confirm that all past allotments and transfers of Equity Shares of the Company have been in compliance with applicable law in India, including the Companies Act, 1956 (to the extent in force at the time of such allotment or transfer) and the Companies Act, 2013, as amended together with the rules and regulations made thereunder. All relevant regulations have been complied with for all previous issuance of Equity Shares.

We further confirm that adequate stamp duty has been paid in respect of allotment of securities by the Company in accordance with applicable law.

We confirm that any changes to the aforesaid capital structure and the notes to capital structure, will immediately be intimated to the Book Running Lead Managers to the IPO, till the date on which the securities of the Company to be issued pursuant to the IPO, start trading on NSE Emerge. In the absence of any communication from us, you may assume that there is no change in respect of the matters covered in this certificate.

This certificate may be relied upon by the legal advisor and the Book Running Lead Managers in relation to the IPO. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the IPO related issue documents.

We hereby indemnify and keep indemnified, saved, defended and harmless the Book Running Lead Managers and Legal Advisor to the proposed IPO of the Company and all persons claiming under them ("Indemnified Persons"), from and against all losses and/or damages arising as a result of the aforementioned representations made by me/us in order to disclose details of the same in the Red Herring Prospectus, the Prospectus, the Abridged Prospectus, for the Issue or arising as a result of any notices, proceedings, litigations, claims, penalties, demands and costs that may be made and/or raised on the Indemnified Persons by any concerned authority(ies) and/or with regard to any matter arising in connection thereto or otherwise by reason of the matter contemplated herein and/or sustained by the Book Running Lead Managers and/or Legal Advisor to the Issue as a result of any statements, representations, assurances, confirmations hereinunder given being untrue.

Yours sincerely,

For and on behalf of Aakaar Medical Technologies Limited



CIN No.: U74900MH2013PLC244717

(Dilip Ramesh Meswani) Founder & Managing Director

DIN: 06540985 Place: Mumbai

C.C:

Legal Advisor to the Issue Vidhigya Associates A-105, Kanara Business Centre, Link Road, Laxmi Nagar, Ghatkopr East, Mumbai -400075 Email: rahul@vidhigyaassociates.com Mobile: +91 8424030160,

Encl.: Certified true copy of the "Capital Structure and Notes to Capital Structure" Chapter of the RHP annexed hereto as Annexure A

Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA

Mob: +91 920317468

E-mail: info@aakaarmedical.in www.aakaarmedical.in GST No: 27AALCA7587Q1ZK

Annexure A CAPITAL STRUCTURE

Details of the share capital of our Company, as on the date of this Red Herring Prospectus, are set forth below.

(in **a**, except share data)

/	=, c.reept siture data)		
Sr. No	Particulars	Aggregate value face value	at Aggregate value at Issue Price*
A.	AUTHORIZED SHARE CAPITAL**		
	1,50,00,000 Equity Shares of face value of 10 each	15,00,00,000	-
B.	ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL BEFORE THE ISSUE	The state of the s	
	1,04,22,416 Equity Shares of face value of ■10 each	10,42,24,160	-
C.	PRESENT ISSUE IN TERMS OF THIS RED HERRING PROSPECTUS^)	
	Fresh Issue up to 37,50,400 Equity Shares of face value of 1 0 each	3,75,04,000	
	Which comprises of:		
	Market Maker Reservation Portion of up to 1,88,800 Equity Shares of face value of 10 each	18,88,000	
	Net Issue of up to 35,61,600 Equity Shares of face value of 10 each	3,56,16,000	
D.	ISSUED, SUBSCRIBED AND PAID-UP CAPITAL AFTER THE ISSUE*		
	[●] Equity Shares of face value ₹10 each		
E.	SECURITIES PREMIUM ACCOUNT		
	Before the Issue	3,88,95,784	
	After the Issue#		

Notes:

Notes to Capital Structure

Share Capital History of our Company

Our Company has only one class of share capital i.e., Equity Shares of face value of 10 each. All the issued Equity Shares are fully paid-up. Our Company has no outstanding convertible instruments as on the date of this Red Herring Prospectus.

Equity Share Capital

The history of the Equity Share capital of our Company is set forth in the table below:



^{*}Subject to finalization Basis of Allotment.

^{**}For details in relation to the changes in the authorized share capital of our Company, see "History and Certain Corporate Matters – Amendments to our Memorandum of Association" on page Error! Bookmark not defined..

[^]The Issue has been authorized by our Board of Directors and our Shareholders pursuant to the resolutions passed at their meetings dated January 06, 2025 and January 07, 2025, respectively.

	Number of Equity Shares allotted	Face value per Equity Share (II)	Issue Price per Equity Share (n)	Nature considera		Nature of allotment/ transfer		
June 20, 2013	10,000	10	10	Cash		Subscription to MOA(1)	10,000	1,00,000
October 05, 2015	90,000	10	10	Cash		Rights Issue(2)	1,00,000	10,00,000
August 25, 2021	6,00,000	10	N.A.	Other Cash	than	Bonus Issue(3)	7,00,000	70,00,000
July 10, 2024	, 14	10	800	Cash		Allotment pursuant to ESOP Scheme(4)	7,00,014	70,00,140
August 06, 2024	6,369	10	800	Cash		Allotment pursuant to ESOP Scheme(5)	7,06,383	70,63,830
August 06, 2024	38,298	10	-	Other Cash	than	Bonus Issue(6)	7,44,681	74,46,810
August 07, 2024	89,36,172	10	-	Other Cash	than	Bonus Issue(7)	96,80,853	9,68,08,530
September 16, 2024	r 3,43,750	10	64	Cash		Preferential allotment(8)		10,02,46,030
October 03, 2024	1,19,844	10	64	Cash		Preferential allotment (9)	1,01,44,447	10,14,44,470
October 07, 2024	2,77,969	10	64	Cash		Preferential allotment (10)	1,04,22,416	10,42,24,160

Allotment of 4,000 Equity Shares to Dilip Ramesh Meswani,3,000 Equity Shares to Bindi Dilip Meswani and 3,000 Equity Shares to Abhash Dilip Meswani pursuant to subscription of MOA. Allotment of 71,001Equity Shares to Dilip Ramesh Meswani,17000 Equity Shares to Bindi Dilip Meswani,1,000 Equity Shares to Abhash Dilip Meswani and 999 Equity Shares to Milouni Dilip Meswani.

Allotment of 4,50,000 Equity Shares to Dilip Ramesh Meswani, 1,20,000 Equity Shares to Bindi Dilip Meswani, 23,400 Equity Shares to Abhash Dilip Meswani, 6,000 Equity Shares to Milouni Dilip Meswani, 600 Equity Shares to Sharda Ramesh Meswani, as Bonus Issue in the ratio of 6:1, i.e. six bonus Equity Shares for every one fully paid-up Equity Shares held by the shareholders of the Company. Allotment of 14 Equity Shares to Rahul Babasaheb Sawakhande in terms of the ESOP scheme.

Allotment of 6,369 Equity Shares to Rahul Babasaheb Swakhande in terms of the ESOP scheme.

Allotment of 38,298 Equity Shares to Rahul Babasaheb Swakhande as Bonus Issue in the ratio of 6:1, i.e. six bonus Equity Shares for every one fully paid-up Equity Shares held by the shareholders of the Company.

Allotment of 63,00,000 Equity Shares to Dilip Ramesh Meswani jointly with Bindi Dilip Meswani, 16,80,000 Equity shares to Bindi Dilip Meswani jointly with Dilip Ramesh Meswani, 7,200 Equity



shares to Sharda Ramesh Meswani jointly with Dilip Ramesh Meswani. 3,27,600 Equity shares to Abhash Dilip Meawani jointly Shurti Mishra, 84,000 Equity shares to Milouni Dilip Meswani jointly with Kunal Jhanwer,1,200 Equity shares to Pranisha Prasad jointly with Rita Meswani, 5,36,172 Equity shares to Rahul Babasaheb Sawakhande as Bonus Issue in the ratio of 12:1, i.e. twelve bonus Equity Shares for every one fully paid-up Equity Shares held by the shareholders of the Company.

Allotment of 1,56,250 Equity Shares to Amit Kumar and Ankita Saraswat (Partners of M.K. Enterprises),78,125 Equity Shares to Ankush Kedai, 78,125 Equity Shares to Finavenue Growth Fund, 31,250 Equity Shares to Deepak Sangwam.

Allotment of 1,19,844 Equity shares to Milouni Dilip Meswani jointly with Kunal Jhanwer.

Allotment of 2,77,969 Equity Shares to Sharda Ramesh Meswani jointly with Dilip Ramesh Meswani.

Preference Share Capital

As on the date of this Red Herring Prospectus, our Company does not have any preference share capital.

Issue of shares for consideration other than cash or out of revaluation of reserves

Except as set out below, our Company has not issued any Equity Shares for consideration other than cash or out of revaluation of reserves at any time since incorporation.

Date o allotmen	f Number o t Equity Shares allotted		Issue Price per Equity Share (n)		Benefits accr to our Compan	1000
August 25, 2021	6,00,000	10		Bonus issue in the ratio of six bonus Equity Shares for every one Equity Share held in the Company(1)	Capitalization reserves	of
August 6, 2024	38,298	10		Bonus issue in the ratio of six bonus Equity Shares for every one Equity Share held in the Company(2)	Capitalization reserves	of
7, 2024	89,36,172		1	Bonus issue in the ratio of or Twelve bonus Equity Shares for a every one Equity Share held in the Company(3)	Capitalization reserves	of

Allotment of 4,50,000 Equity Shares to Dilip Ramesh Meswani,1,20,000 Equity Shares to Bindi Dilip Meswani, 23,400 Equity Shares to Abhash Dilip Meswani, 6,000 Equity Shares to Milouni Dilip Meswani, 600 Equity Shares to Sharda Ramesh Meswani, as Bonus Issue in the ratio of 6:1, i.e.,six bonus Equity Shares for every one fully paid-up Equity Shares held by the shareholders of the Company. Allotment of 38,298 Equity Shares to Rahul Babasaheb Swakhande as Bonus Issue in the ratio of 6:1, i.e. six bonus Equity Shares for every one fully paid-up Equity Shares held by the shareholders of the Company.

Allotment of 63,00,000 Equity Shares to Dilip Ramesh Meswani jointly with Bindi Dilip Meswani, 16,80,000 Equity shares to Bindi Dilip Meswani jointly with Dilip Ramesh Meswani, 7,200 Equity shares to Sharda Ramesh Meswani jointly with Dilip Ramesh Meswani. 3,27,600 Equity shares to Abhash Dilip Meswani jointly Shurti Mishra, 84000 Equity shares to Milouni Dilip Meswani with Kunal Jhanwer,1200 Equity shares to Pranisha Prasad Jointly with Rita Meswani, 5,36,172 Equity shares to Rahul Babasaheb Sawakhande as Bonus Issue in the ratio of 12:1, i.e. Twelve bonus Equity Shares for every one fully paid-up Equity Shares held by the shareholders of the Company.



Issue of Equity Shares pursuant to schemes of arrangement

Our Company has not allotted any Equity Shares pursuant to a scheme of amalgamation approved under Section 391 to 394 of the Companies Act, 1956 or Sections 230 to 234 of the Companies Act, 2013.

Issue or transfer of Equity Shares under employee stock option schemes

As on the date of this Red Herring Prospectus, our Company has adopted the Aakaar Employee Stock Option Plan 2021 ("ESOP 2021") pursuant to the resolutions passed by our Board on March 10, 2021 and our Shareholders on April 01, 2021. All grant of options under the ESOP 2021 is in compliance with Companies Act, 2013 and have been made to employees of our Company. As on date of this Red Herring Prospectus, there have been allotments made under ESOP 2021. The details of the ESOP 2021, as certified by M/s C B Mehta & Associates, Chartered Accountants, through a certificate dated June 14, 2025 are as follows:

Particulars	For the Financial year ended March 31,	For the Financial year ended March 31,	For the Financial year ended March 31,	From April 1, 2025 till the date of this RHP
	2023	2024	2025	NTII
Total options outstanding as at the beginning of the period	6,383	6,383	6,383*	Nil
Total Options granted during the Fiscal/ period	N.A	N.A	6,383	N.A
Options forfeited/lapsed/cancelled during the fiscal/ period	Nil	Nil	Nil	N.A
Variation of terms of options	N.A	N.A	Nil	N.A
Total number of options in	N.A	N.A	6,383	N.A
force	N.A	N.A	6,383	N.A
Total options vested Options exercised during the fiscal/ period	N.A	N.A	6,383	N.A
Money realized by exercise of options during the year/period	N.A	N.A	51,06,400	N.A
Total number of Equity Shares that would arise as a result of full exercise of options granted		N.A	6,383	N.A
Employee wise details of options granted to:			a	
(i) Key Managerial Personnel and Senion Management Personnel			Part of the last o	
Rahul Babasaheb Sawakhande		N.A	6,383	N.A
(ii) Any other employee who receives a grant in any	e /			



one year of options amounting to 5% or more of the options granted during the year (iii) Identified employees N.A N.A N.A N.A who were granted options during any one year equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of Company at the time of grant Diluted earnings per share Particulars For the For the For the pursuant to the issue of Financial Financial Financial Equity Shares on exercise of year year year options calculated in ended ended ended accordance with the March March March applicable accounting 31, 2023 31, 2024 31, 2025 standard on 'Earnings Per Restated 2.36 3.14 6.13 Share' (in) Diluted earnings per equity share

Where the Company has calculated the employee compensation cost using the intrinsic value of the stock options, the difference, if any, between employee compensation cost computed and the employee compensation cost that would have been recognised if it had used the fair value of the stock options and the impact of this difference on the profits and on the earnings per share of the Company

Description of the pricing formula and the method and significant assumptions used during the year to estimate the fair values of options, including weighted-average information, namely, risk-free interest rate, expected life, expected volatility, expected dividends and the price of the underlying share in market at the time of

Risk-free interest rate	4.62% for 3 years
Expected life	3 Years
Expected volatility	It is taken from Ashwath Damodaran
Expected dividend yield	0.00%
Price of the underlying	Rs. 841.37 for Options vesting on 31st July, 2024.



grant of the option

Exercise price of options in a (as on the date of grant options)

■800 per share

Impact on the profits and on the earnings per share of the last three years if the accounting specified in the Securities (Share India Benefits Employee the last three years

policies and Exchange Board of Based and Sweat Equity) Regulations, 2021 had been followed, in respect of options granted in Intention of key managerial N.A personnel, senior

management and wholetime directors who are holders of Equity Shares allotted on exercise of options granted under the ESOP Scheme to sell their shares within three months after the listing of Equity Shares pursuant to the Offer Intention to sell Equity Shares arising out of the ESOP Scheme within three months after the date of listing of Equity Shares, by directors, key managerial senior personnel, management and employees Shares Equity having arising out of the ESOP

Scheme, amounting to more than 1% of the issued capital

(excluding

The accounting policies specified in the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 have been followed in the restated financial statements. Therefore, the profit and earnings per share have complied with such policies.

N.A

warrants and conversions) *ESOPS were exrecied on July 10, 2024 and August 6, 2025. # As per Fair Valuation Report of ESOPs dtd. 01/08/2021

outstanding

Issue of shares at a price lower than the Issue Price in the last year

The Issue Price for the Equity Shares is ₹ [•]. Except for the bonus issue of shares and Share Issued under Prefrential Allotment dated September 16, 2024, October 03, 2024, October 07, 2024, our Company has not issued any shares in the last year. For details of the allotments made in the last one year, see "Capital Structure - Share Capital History of Our Company - Equity Share capital" on [●] of this Red Herring Prospectus.



[Remainder of the page has been intentionally left blank]



Shareholding Pattern of our Company

Snareholding Lautein of Control o	the date of this Red Herring Prospectus.	description of the contract of	The table below presents the equity smarchoning presents
Shareno			The tabl

Number Numb Number Total Shareholdin pattern of the country shareholding pattern of the control of fullyer of shareholding pattern of shareholdin cach class offor sharenges as a felocked in state and the control of fullyer of shareholdin cach class offor sharenges as a felocked in cach class belief in cach class of fullyer offor sharesof totals curities (IX) and the conversion of the country paid-rap of the conversion of t
--

	2.4	*
	12	1 1
	# 16	
		%00
	į. II	,04,22,41,04,22,4100% - 6 16
		4,22
	ì	0,1
		22,4
		,04,0
	SIS	
		100
	ř	,04,22,4 100% 6
		2,4
		74,2
	1.0	1,0
	1 1	i :
		3 E
	* i	4
		1,04,22,4
	ř	1,0
		7.
yin	tor pts by	
nderlyin	depositor y receipts Shares - held by employe	e trusts Total (A+B+C)
in a	dej y r Shi hel	e tr Tot (A+
	(22)	

(C2)



Mob: +91 9820317468 E-mail: info@aakaarmedical.in www.aakaarmedical.in GST No: 27AALCA7587Q1ZK

Other details of shareholding of our Company

As on the date of the filing of this Red Herring Prospectus, our Company has 11 Shareholders.

Set forth below are the details of the build-up of our Promoters' shareholding in our Company since incorporation:

llotment/ equisitio / transfer	of Equity Shares	per Equit	Price/Considerati on per Equity Share (u)	Nature considera n	of Nature of tio allotment/ transfer	Cumulativ e number of Equity Shares	Issue capital*(1	Post-
Dilip Rame	esh Meswa	ni		0.1	Subscriptio	4 000	Negligibl	
June 20, 2013	4,000	10	10	Cash	n to MOA		e Negligibl	
September 15, 2015	(1)	10	10	Cash	Transfer of Equity Shares to Milouni Meswani		e e	
October 05, 2015	71,001	10	10	Cash	Rights Issue	75,000	Negligibl e	= ==
August 25, 2021	4,50,000	10	N.A.	Other Cash	Company	ty or ne ty ld	5.04	
August 07, 2024	63,00,00	00 10		Other Cash	twelve (1) Equity Shares every (1) Equ	of 2) for one city eld the		
Sub-tota (A)	al 68,25,0	000					65.48	
33.4	ilip Meswa	ani				.:- 2.000	Neglig	ihl [a]
The second second	20, 3,000	10	10	Cash	Subscrip	otio 3,000	reging	.o. [•]

Mumbai © Delhi © Bangalore © Chennai © Hyderabad © Kolkata © Patna © Chandigarh © Pune © Indore © Ahmedabad



Mob: + 91 9820317468 E-mail: info@aakaarmedical.in

							akaarmedic		
allotment/ acquisitio n/ transfer	of Equity Shares	value per Equit	Issue Price/Considerati on per Equity Share (II)	Nature consider n			Cumulativ e number of Equity Shares	Issue	Post-
2013						n to MOA	m.	e	
October 05, 2015	17,000	10	10	Cash	-	Rights Issue	20,000	Negligibl e	
August 25, 2021	1,20,000	10	N.A.	Other Cash	than	Bonus issue in the ratio of six (6) Equity Shares for every one (1) Equity Share held in the Company		1.34	
August 7, 2024	16,80,000	10	N.A.	Other Cash	than	Bonus issue in the ratio of twelve (12) Equity Shares for every one (1) Equity Share held in the Company		17.46	
Sub-total (B)	18,20,000		The .					17.46	[•]
	- 86,45,000)						82.94	

^{*}The figures in the row have been rounded-off to the closest decimal.

Details of the transfer and acquisition of Equity Shares of our Company through secondary transaction for the Promoters, and members of the Promoter Group.

Except as disclosed below, our Promoters and members of the Promoter Group have not transferred or acquired Equity Shares of our Company through secondary transactions:

Date of transfer	Name of a transferee	allotee/	Transfe	ror	No. of Equity shares transferred	Face value of Equity shares (II)	Price per Equity Share/Nature of consideration (n)
September	Milouni	Dilip	Dilip	Ramesh	1	10	10

Mumbai 🛈 Delhi 🔘 Bangalore 🛈 Chennai 🛈 Hyderabad 🛈 Kolkata 🛈 Patna 🛈 Chandigarh 🔘 Pune 🔘 Indore 🔘 Ahmedabad



Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road

A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA Mob: + 91 9820317468

E-mail: info@aakaarmedical.in www.aakaarmedical.in

15, 2015	Meswani	Meswani		GST No: 27AALCA75	
June 01, 2020	Shardha Ramesh Meswani	Abhash Dilip Meswani	100	10	503
June 06, 2024	Pranisha Prasad	Shardha Ramesh Meswani	100	10	200

Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company, as on the date of this Red Herring Prospectus.

Sr. No.	Name of the Shareholder		ofPercentage of the es Equity Share capital
1	Dilia Bassah Massari	60.05.000	(%)*
1.	Dilip Ramesh Meswani	68,25,000	65.48
2.	Bindi Dilip Meswani	18,20,000	17.46
3.	Rahul Babasaheb Sawakhande	5,80,853	5.57
4.	Abhash Dilip Meswani	3,54,900	3.41
5.	Sharda Ramesh Meswani	2,85,769	2.74
6.	Milouni Dilip Meswani	2,10,844	2.02
7.	Grobiz Sme Opportunity Fund	1,56,250	1.50
Tota	d	1,02,33,616	98.18
*Ro	unded off to the closest decimal		

Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company, as of 10 days prior to the date of this Red Herring Prospectus.

Sr.	Name of the Shareholder	Number of Equity Shares	Percentage of the Equity
No.			Share capital (%)*
1.	Dilip Ramesh Meswani	68,25,000	65.48
2.	Bindi Dilip Meswani	18,20,000	17.46
3.	Rahul Babasaheb Sawakhande	5,80,853	5,57
4.	Abhash Dilip Meswani	3,54,900	3.41
5.	Sharda Ramesh Meswani	2,85,769	2.74
6.	Milouni Dilip Meswani	2,10,844	2.02
7.	Grobiz Sme Opportunity Fund	1,56,250	1.50
Tota	al	1,02,33,616	98.18
*Ro	ounded off to the closest decimal		

Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Company, on a fully diluted basis, as of one year prior to the date of this Red Herring Prospectus.

Sr. No.	Name of the Shareholder	Number of Shares	EquityPercentage of the Equity Share capital (%)*
1.	Dilip Ramesh Meswani	5,25,000	75.00
2.	Bindi Dilip Meswani	1,40,000	20.00
3.	Abhash Dilip Meswani	27,300	3.90
4.	Milouni Dilip Meswani	7,000	1.00
Tot	al	6,99,300	99.90

^{*}Rounded off to the closest decimal

Set forth below is a list of Shareholders holding 1% or more of the paid-up Share Capital of our Mumbai © Delhi © Bangalore © Chennai © Hyderabad © Kolkata © Patna © Chandigarh © Pune © Indore © Ahmedabad



Mob: + 91 9820317468 E-mail: info@aakaarmedical.in

www.aakaarmedical.in

Company, on a fully diluted basis, as of two years prior to the date of this Republications.

Sr. Name of the Shareholder	Number of Shares	EquityPercentage of the Equity Share capital (%)*
1. Dilip Ramesh Meswani	5,25,000	75.00
2. Bindi Dilip Meswani	1,40,000	20.00
Abhash Dilip Meswani	27,300	3.90
Milouni Dilip Meswani	7,000	1.00
Total	6,99,300	99.90

^{*}Rounded off to the closest decimal

The aggregate shareholding of the Promoters and Promoter group

Sr. No.	Name of the Shareholder	Number of Shares	Pre-Issue	of thePercentage of the EquityPost-Issue Equity (%)* Share capital (%)
Pror	noters	and the second s		
1.	Dilip Ramesh Meswani	68,25,000	65.48	
2.	Bindi Dilip Meswani	18,20,000	17.46	
	Sub-total (A)	86,45,000	82.94	[0]
Pror	noter Group			
1.	Abhash Dilip Meswani	3,54,900	3.41	
2.	Milouni Dilip Meswani	2,10,844	2.02	
3.	Sharda Ramesh Meswani	2,85,769	2.74	
٥.	Sub-total (B)	8,51,513	8.17	
Tota	The state of the s	94,96,513	91.11	

^{*}Rounded off to the closest decimal

The number of specified securities purchased or sold by the Promoter Group and/ or by the Directors of our Company and their relatives in the preceding six months.

Except as stated below, there has been no purchase or sale of securities by our Promoters and Promoter Group or by the Directors of our Company and their relatives in the preceding six months from the date of this Red Herring Prospectus:

Date allotment	of Number Equity Shares allotted	of Face per Share	value Iss Equity per Sh		Nature allotment/ transfer	of Percentage of the Pre-Issue Equity Share capital (%)
October 2024	03, 1,19,844	-	64	Cash	Preferential allotment (1)	1.15
October 2024	07, 2,77,969	10	64	Cash	Preferential allotment(2)	2.67
2021						

Allotment of 1,19,844 Equity shares to Milouni Dilip Meswani jointly with Kunal Jhanwer. Allotment of 2,77,969 Equity Shares to Sharda Ramesh Meswani jointly with Dilip Ramesh Meswani.

Details of lock-in

Pursuant to the Regulation 236 and 238 of the SEBI (ICDR) Regulations, an aggregate of 20% of the Post-Issue Equity Share Capital held by our Promoter shall be considered as promoter's contribution

Mumbai 🛈 Delhi 🔘 Bangalore 🛈 Chennai 🛈 Hyderabad 🛈 Kolkata 🛈 Patna 🛈 Chandigarh 🛈 Pune 🔘 Indore 🔘 Ahmedabad



Mob: +91 9820317468 E-mail: info@aakaarmedical.in

www.aakaarmedical.in ("Promoter's Contribution") and locked-in for a period of three years from the Adata of Adata of Adata of the Promoter's Contribution would be created as per applicable law and procedure and details of the same shall also be provided to the Stock Exchange before listing of the Equity Shares.

Name of Promoters	Number Equity Shares locked-in		t transaction	per Equity	Acquisition	of the pre-	post- Issue	to which Equity Shares
Dilip Ramesh Meswani	22,37,814	August 7, 2024	Bonus Issue	10	N.A.	21.47	[•]	3 years
Bindi Dilip Meswani	5,96,750	August 7, 2024	Bonus Issue	10	N.A.	5.72	[•]	3 years
Total	28,34,564				N.A.	27.20		

The shareholding of the Promoters in excess of 20% of the fully diluted Post-Issue Equity Share capital shall be locked in for a period of one year from the date of Allotment.

All the Equity Shares held by our Promoters are in dematerialized form.

The Equity Shares held by shareholders other than promoter shall be locked-in for a period of one (1) year from the date of Allotment in the Issue except for any Equity Shares held by the eligible employees (whether currently employees or not and including the legal heirs or nominees of any deceased employees or ex-employees, the same may be transferred to any other person holding the Equity Shares which are locked-in, subject to continuation of the lock-in in the hands of transferees for the remaining period (and such transferees shall not be eligible to transfer until the expiry of the lock-in period) and compliance with the Takeover Regulations.

In this connection, please note that:

The Equity Shares issued for Promoter's contribution do not include (i) Equity Shares acquired in the three immediately preceding years for consideration other than cash and revaluation of assets or capitalization of intangible assets was involved in such transaction, (ii) Equity Shares resulting from bonus issue by utilization of revaluation reserves or unrealized profits of our Company or bonus shares issued against Equity Shares, which are otherwise ineligible for computation of minimum Promoter's contribution.

The minimum Promoter's contribution does not include any Equity Shares acquired during the immediately preceding one year at a price lower than the price at which the Equity Shares are being issued to the public in the Issue.

Our Company has not been formed by the conversion of one or more partnership firms or a limited liability partnership firm.

As on the date of this Red Herring Prospectus, none of the Equity Shares held by our Promoters are Mumbai © Delhi © Bangalore © Chennai © Hyderabad © Kolkata © Patna © Chandigarh © Pune © Indore © Ahmedabad



Mob: + 91 9820317468 E-mail: info@aakaarmedical.in www.aakaarmedical.in GST No: 27AALCA7587Q1ZK

pledged.

In terms of Regulation 243 of the SEBI ICDR Regulations, Equity Shares held by our Promoters which are locked-in as per Regulation 238 of the SEBI ICDR Regulations, may be transferred to the other Promoters or any member of our Promoter Group or a new promoter, subject to continuation of lock-in applicable with the transferee for the remaining period (and such transferees shall not be eligible to transfer until the expiry of the lock-in period) and compliance with provisions of the Takeover Regulations.

Further, in terms of Regulation 243 of the SEBI ICDR Regulations, Equity Shares held by persons (other than our Promoters) prior to the Issue and locked-in for a period of one year, may be transferred to any other person holding Equity Shares which are locked-in along with the Equity Shares proposed to be transferred, subject to the continuation of the lock-in with the transferee for the remaining period (and such transferees shall not be eligible to transfer until the expiry of the lock-in period) and compliance with the provisions of the Takeover Regulations.

There have been no financing arrangements whereby our Promoters, members of the Promoter Group, our Directors and their relatives have financed the purchase by any other person of securities of our Company during the six months immediately preceding the date of filing of this Red Herring Prospectus.

Except for the allotment of Equity Shares pursuant to the Issue, our Company presently does not intend or propose to alter its capital structure for a period of six months from the Issue Opening Date, by way of split or consolidation of the denomination of Equity Shares, or by way of further issue of Equity Shares (including issue of securities convertible into or exchangeable, directly or indirectly for Equity Shares), whether on a preferential basis, or by way of issue of bonus shares, or on a rights basis, or by way of further public issue of Equity Shares, or otherwise. However, if our Company enters into acquisitions, joint ventures or other arrangements, our Company may, subject to necessary approvals, consider raising additional capital to fund such activity or use Equity Shares as currency for acquisitions or participation in such joint ventures.

There will be no further issue of Equity Shares whether by way of issue of bonus shares, preferential allotment, rights issue or in any other manner during the period commencing from filing of this Red Herring Prospectus with SEBI until the Equity Shares have been listed on the Stock Exchanges or all application moneys have been refunded to the Investors, or the application moneys are unblocked in the ASBA Accounts on account of non-listing, under-subscription etc., as the case may be.

Our Company, our Directors and the Book Running Lead Manager have no existing buy-back arrangements or any other similar arrangements for the purchase of Equity Shares being offered through the Issue.

All Equity Shares offered pursuant to the Issue shall be fully paid-up at the time of Allotment and there are no partly paid-up Equity Shares as on the date of this Red Herring Prospectus.

Except as disclosed in "Risk Factors" no 28 on page 59, the Company is in compliance with the Companies Act,

2013 with respect to issuance of securities since inception till the date of filing of Red Herring Prospectus

As on the date of this Red Herring Prospectus, the Book Running Lead Manager and their respective associates (as defined under the Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992) do not hold any Equity Shares of our Company. The Book Running Lead Manager

Mumbai 🛈 Delhi 🛈 Bangalore 🛈 Chennai 🛈 Hyderabad 🛈 Kolkata 🛈 Patna 🛈 Chandigarh 🛈 Pune 🛈 Indore 🛈 Ahmedabad



Aakaar Medical Technologies Limited (formerly: Aakaar Medical Technologies Pvt.Ltd.) A-801, Heritage Plaza, Teli Gali Cross Road Andheri (East), Mumbai – 400 069 INDIA Mob: +91 9820317468 E-mail: info@aakaarmedical.in

and their affiliates may engage in the transactions with and performs www.aakaarmedical.in ordinary course of business or may in the future engage in commercial banking and investment banking transactions with our Company for which they may in the future receive customary compensation.

There are no outstanding convertible securities, options or rights to convert debentures, loans or other instruments into Equity Shares as on the date of this Red Herring Prospectus.

Our Company shall ensure that transactions in the Equity Shares by the Promoter Group between the date of filing the draft offer documents with the Registrar of Companies and the Issue Closing Date shall be reported to the Stock Exchanges within twenty-four hours of such transaction.

No person connected with the Issue, including, but not limited to, the Book Running Lead Manager, the members of the Syndicate, our Company and Directors shall offer any incentive, whether direct or indirect, in any manner, whether in cash or kind or services or otherwise to any Investor for making an Application.

There shall be only one denomination of the Equity Shares, unless otherwise permitted by law. Our Company shall comply with such disclosure and accounting norms as may be specified by SEBI from time to time.

[Remainder of the page has been intentionally left blank]

